BEAM
Beam Therapeutics Inc. Healthcare - Biotechnology Investor Relations →
Beam Therapeutics Inc. (BEAM) closed at $24.63 as of 2026-03-20, trading 18.2% below its 200-week moving average of $30.09. This places BEAM in the extreme value zone. The stock is currently moving closer to the line, down from -16.6% last week. The 14-week RSI sits at 43, indicating neutral momentum.
Trading volume is running at 1.4x of its 14-week average, which is in the normal range. The balance between buying and selling volume (1.14 ratio) is neutral — neither side is clearly dominating.
Over the past 271 weeks of data, BEAM has crossed below its 200-week moving average 4 times. On average, these episodes lasted 52 weeks. The average one-year return after crossing below was -41.5%, suggesting these dips have not historically been reliable buying opportunities for this stock.
With a market cap of $2.5 billion, BEAM is a mid-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at -8.1%. The stock trades at 2.0x book value.
Share count has increased 42.8% over three years, indicating dilution.
Over the past 5.2 years, a hypothetical investment of $100 in BEAM would have grown to $26, compared to $188 for the S&P 500. BEAM has returned -22.9% annualized vs 12.8% for the index, underperforming the broader market over this period.
Free cash flow has been declining. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: BEAM vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After BEAM Crosses Below the Line?
Across 4 historical episodes, buying BEAM when it crossed below its 200-week moving average produced an average return of -41.7% after 12 months (median -49.0%), compared to +0.0% for the S&P 500 over the same periods. After 24 months, the average return was -50.7% vs +25.7% for the index.
Each line shows $100 invested at the moment BEAM crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
BEAM has crossed below its 200-week MA 4 times with an average 1-year return of +-41.5% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Jan 2022 | Feb 2022 | 1 | 1.3% | -21.0% | -59.8% |
| Mar 2022 | Jul 2022 | 19 | 45.2% | -47.2% | -59.6% |
| Aug 2022 | Jan 2026 | 178 | 66.4% | -56.2% | -53.8% |
| Jan 2026 | Ongoing | 8+ | 18.2% | Ongoing | -10.8% |
| Average | 52 | — | +-41.5% | — |
Frequently Asked Questions
Is BEAM below its 200-week moving average?
Yes. As of 2026-03-20, Beam Therapeutics Inc. (BEAM) is trading 18.2% below its 200-week moving average of $30.09. The current price is $24.63.
What is BEAM's 200-week moving average price?
Beam Therapeutics Inc.'s 200-week moving average is $30.09 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when BEAM drops below its 200-week moving average?
BEAM has crossed below its 200-week moving average 4 times in our data. The average one-year return after these crossings was -41.5%, meaning the dips were not reliable buying signals for this particular stock. These episodes lasted 52 weeks on average.
Is BEAM a good value right now?
Here's what our data says about BEAM as of 2026-03-20: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 43. Free cash flow is currently negative. Return on equity is -8.1%. Price-to-book is 2.0x. This is not a buy or sell recommendation — always do your own research.
How does BEAM compare to the S&P 500?
Over the past 5.2 years, $100 invested in BEAM would have grown to $26, compared to $188 for the S&P 500. That's -22.9% annualized vs 12.8% for the index. BEAM has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-03-20